中国麻风皮肤病杂志 ›› 2025, Vol. 41 ›› Issue (9): 692-696.doi: 10.12144/zgmfskin202509692

• 综述 • 上一篇    下一篇

乌帕替尼皮肤科超说明书应用进展

焦雨竹1,2,李慧杰1,2,杨青1,2   

  1. 1山东第一医科大学附属皮肤病医院,山东济南，250022； 2山东省皮肤病性病防治研究所，山东济南，250022
  • 出版日期:2025-09-15 发布日期:2025-09-08

Update on off-label use of upadacitinib in dermatology

JIAO Yuzhu1,2, LI Huijie1,2, YANG Qing1,2   

  1. 1 Dermatology Hospital of Shandong First Medical University, Jinan 250022, China; 2 Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan 250022, China
  • Online:2025-09-15 Published:2025-09-08

PDF (PC)

61

摘要： 乌帕替尼是一种高选择性JAK1抑制剂，目前已在我国批准用于特应性皮炎、类风湿性关节炎、银屑病关节炎、克罗恩病、溃疡性结肠炎、强直性脊柱炎以及放射学阴性中轴型脊柱关节炎的治疗，覆盖皮肤、消化以及风湿免疫等领域。近年研究表明，其在化脓性汗腺炎、斑秃、白癜风、系统性红斑狼疮、掌跖脓疱病等自身免疫性疾病或炎症性皮肤病中展现出显著疗效。本文系统综述乌帕替尼的作用机制、临床疗效及安全性数据，结合近年随机对照试验和真实世界研究，探讨其在皮肤科的应用潜力，为临床实践提供循证依据。

关键词: 乌帕替尼, 炎症性皮肤病, 超说明书使用

Abstract: Upadacitinib, a highly selective JAK1 inhibitor, has been approved in China for the treatment of multiple immune-mediated disorders including atopic dermatitis, rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis, demonstrating therapeutic applications across dermatological, gastroenterological, and rheumatological domains. Recent studies have shown that it exhibits significant efficacy in autoimmune diseases or inflammatory dermatoses such as hidradenitis suppurativa, alopecia areata, vitiligo, and palmoplantar pustulosis. This review comprehensively summarizes the pharmacological mechanisms, clinical efficacy, and safety profile of upadacitinib, integrating data from recent randomized controlled trials and real-world studies to evaluate its expanding therapeutic potential in dermatology. The synthesis of current evidence aims to provide clinicians with evidence-based guidance for optimizing treatment strategies in inflammatory skin disorders.

Key words: upadacitinib, inflammatory dermatoses, off-label use